EUROPHARMACEUTICALS

Active

Public limited companyfounded 1984active for 42 yearsWolvendaellaan 21, 1180 Ukkel, BelgiumKBO/BCE: BE 0425.594.923

From the official registers: KBO 38 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

The computed 12-month bankruptcy probability of EUROPHARMACEUTICALS is 2.1% (moderate). The 2025 annual accounts show negative equity (-€2,911) and a net result of -€19,213. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 18% of 13,692 sector peers (NACE 46, financial year 2025). The company has been active since 1984 and the Belgian Official Gazette contains no insolvency signals. The KBO does carry 1 administrative register entry (see administrative flags).

Risk analysisFollow Report Compare

EUROPHARMACEUTICALSActiveChecked score 52/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 29-03-1984 Normal situation
Legal form: Public limited company
Registered office: Wolvendaellaan 21, 1180 Ukkel
Activity: Wholesale of pharmaceutical and medical goods NACE 46460and 2 others
Establishment unit: 2.029.628.691 1180 Ukkel, since 23-07-1987
Financial year end: 31 December
Peppol: Reachable since 21-08-2025

Company details

Who decides

Board

GECZY Marie-Laurence PascaleDirector
GÉCZY József MihályDirector

Board & ownership

How it is doing

52 Fair Checked score 2025

Bankruptcy probabilitywithin 12 months: 2.1%

Annual accounts 2025

Gross margin: -€15,369; ▼ 371%
Loss: €19,213; ▲ 22.6%
Equity: -€2,911
Total assets: €54,573; ▼ 18.1%

Turnover not published (micro format)2025 accounts 45 days early

Filed on 16-06-2026PDF

Financials

Why 52raises riskLoss of €19,213, the second in a row (financial year 2025)Negative equity -€2,911lowers riskSize: total assets €54,573Founded in 1984Show the evidence

Checked score

Score 2025

52 / 100

Fair

Probability in this band: 1.5% to 4.2%

Financially better than 19% of its sector peers (NACE 46, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 20-29

equity -5.3% of total assets

Liquidity 50+3

short-term debt 105.3% · cash 40.6%

Profitability 0=

return on assets -35.2%

Bankruptcy probability, 12 months

2.1% Moderate

0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (26,900 companies, NACE 46, micro)

Last 24 months 11-2024: 0.4% 12-2024: 0.4%● unchanged vs 11-2024 01-2025: 0.4%● unchanged vs 12-2024 02-2025: 0.4%● unchanged vs 01-2025 03-2025: 0.4%● unchanged vs 02-2025lowest value 04-2025: 0.4%● unchanged vs 03-2025 05-2025: 0.7%▲ +0.3 percentage points vs 04-2025 06-2025: 0.7%● unchanged vs 05-2025 07-2025: 0.9%▲ +0.2 percentage points vs 06-2025 08-2025: 1.3%▲ +0.4 percentage points vs 07-2025 09-2025: 1.5%▲ +0.2 percentage points vs 08-2025 10-2025: 1.4%▼ -0.1 percentage points vs 09-2025 11-2025: 1.4%● unchanged vs 10-2025 12-2025: 1.4%● unchanged vs 11-2025 01-2026: 1.4%● unchanged vs 12-2025 02-2026: 1.4%● unchanged vs 01-2026 03-2026: 1.3%▼ -0.1 percentage points vs 02-2026 04-2026: 1.4%▲ +0.1 percentage points vs 03-2026 05-2026: 1.3%▼ -0.1 percentage points vs 04-2026 06-2026: 1.5%▲ +0.2 percentage points vs 05-2026 07-2026: 2.1%▲ +0.6 percentage points vs 06-2026highest value 08-2026: 2.1%● unchanged vs 07-2026highest value 09-2026: 2.1%● unchanged vs 08-2026highest value 10-2026: 2.1%● unchanged vs 09-2026highest value

No credit on open account

Liquidity insufficient (current ratio 0.47, compared with 0.74 in 2024, below 1; short-term debt: 105.3% and cash: 40.6% of total assets), and equity is negative.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro): better than 15% on solvency, 51% on liquidity, 6% on profitability and 4% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Seven signals.

lowers riskraises riskneutral

Size: total assets €54,573

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Loss of €19,213, the second in a row (financial year 2025)

NBB · annual accounts

Negative equity -€2,911

NBB · annual accounts

Founded in 1984

Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.

KBO

Negative equity

The 2025 annual accounts show negative equity and a net loss.

NBB · annual accounts 2025

Equity per financial year

1819202122232425

2018 to 2025 · latest year -€2,911

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-06-2026, 45 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

45 days early

2024

39 days late

2023

92 days late

2022

113 days late

2021

124 days late

2020

108 days late

2019

111 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 77 days after the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Administrative warnings in the KBO publications

1 publication by the FPS Economy about this company, such as a strike-off for address, accounts or UBO, or its withdrawal.

KBO publications

Publications

UBO non-compliance

Searched, nothing found (1)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 1 November (4 of the last 5 filed years within 54 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

Key points

Risk: Negative equityfinancial year 2025: debts exceed assets -€2,911 View
Caution: Among the weakest 12% on net resultsector median €5,670 · 13,698 companies -€19,213 View
Caution: 2 loss-making years in a rowloss financial year 2025 -€19,213 View

Documents

Key facts about EUROPHARMACEUTICALS

What is the company number of EUROPHARMACEUTICALS?: 0425.594.923. In Belgium the VAT number is the company number with BE in front: BE 0425.594.923.
Where is EUROPHARMACEUTICALS based?: The registered office is at Wolvendaellaan 21, 1180 Ukkel.Company details
What does EUROPHARMACEUTICALS do?: According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of EUROPHARMACEUTICALS?: Public limited company (NV).
When was EUROPHARMACEUTICALS founded?: On 29-03-1984.
Is EUROPHARMACEUTICALS still active?: Yes, EUROPHARMACEUTICALS is an active enterprise in the KBO register.
What is the turnover of EUROPHARMACEUTICALS?: The annual accounts for financial year 2025 state no turnover: the micro format does not require it.Financials
Is EUROPHARMACEUTICALS profitable?: In financial year 2025, EUROPHARMACEUTICALS made a loss of €19,213.
Where can I find the annual accounts of EUROPHARMACEUTICALS?: EUROPHARMACEUTICALS filed 38 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
When are the next annual accounts of EUROPHARMACEUTICALS due?: By 31-07-2027, for financial year 2026.Timeline